Predictors of Trastuzumab-induced Cardiotoxicity in Breast Cancer Patients

Recruiting

• Conditions: Breast cancer patient; Trastuzumab; Cardiotoxicity; Breast cancer

• Registration Number: TCTR20210209001
• Lead Sponsor: Faculty of medicine, Chiang Mai University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-02-09
• Study Completion: 2021-12-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 250

Inclusion Criteria

Diagnosed with breast cancer with HER-2 positive and treated with Trastuzumab
Available of left ventricular function data during trastuzumab therapy

Exclusion Criteria

LVEF < 50% before trastuzumab therapy
Severe valvular heart disease
Prior history of chemotherapy for other cancers

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cardiac event 1 year left ventricular ejection fraction

Secondary Outcome Measures

Name	Time	Method
/A N/A N/A